Denosumab, a RANKL-specific monoclonal antibody, is not only an effective treatment for postmenopausal osteoporosis, but also reduces local bone loss in patients with rheumatoid arthritis [37, 38]. This evidence concerns the gene TNFSF11 and rheumatoid arthritis.